Biotin-LC Alpha-Synuclein (51-70) Peptide

Product Name
Biotin-LC Alpha-Synuclein (51-70) Peptide
Product Quantity
4 mg
Catalog Number
LT8708
Sequence
GVATVAEKTKEQVTNVGGAV
Gly-Val-Ala-Thr-Val-Ala-Glu-Lys-Thr-Lys-Glu-Gln-Val-Thr-Asn-Val-Gly-Gly-Ala-Val
Purity
>95%
Modifications
LCbiot, 1mg/vial
Peptide Type
Human alpha-synuclein research fragment
Scientific Background

The NAC region, roughly residues 61 to 95, is what makes alpha-synuclein aggregate. Beta-synuclein lacks part of this stretch and does not assemble comparably, which is the clearest natural demonstration that the segment is the determining factor. This peptide runs from residue 51 into the start of it.

Hydrophobic residues within NAC have been shown to drive formation of seed-competent fibrils — the species able to template further aggregation rather than merely existing as aggregate — and the region is the target of peptide inhibitors designed to interrupt templating. Work here therefore concerns aggregation kinetics, seeding and inhibitor design rather than the membrane biology that dominates the N-terminal peptides.

One consequence deserves anticipating: a peptide reaching into the hydrophobic core can itself aggregate under some conditions. Solubility, storage and the aggregation state at the time of use are variables here in a way they are not for the N-terminal members of this series, and characterising the material as applied is worth doing rather than assuming a monomeric starting point.

Research Applications
  • Thioflavin T aggregation kinetics and seeded fibril formation
  • Screening peptide inhibitors directed at the hydrophobic NAC core
  • Seed-competence assays distinguishing templating from bulk aggregation
  • Electron microscopy and structural characterisation of assemblies
  • Epitope localisation alongside the 41-60 and 91-110 peptides
References

1. Initiation and progression of alpha-synuclein pathology in Parkinson's disease. Cellular and Molecular Life Sciences (2022). CMLS 2022

2. The Parkinson disease gene SNCA: evolutionary and structural insights with pathological implication. Scientific Reports (2016). Sci Rep 2016

3. Hydrophobic residues in the alpha-synuclein NAC domain drive seed-competent fibril formation and are targeted by peptide inhibitors. PMC12797002

4. Peptide-based approaches to directly target alpha-synuclein in Parkinson's disease. (2023). PMID 37940962

  • 1 Units in Stock
Ask a Question

Add to Cart: